Juan Pablo Munoz
Overview
Explore the profile of Juan Pablo Munoz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larrosa C, Simao-Rafael M, Salvador N, Munoz J, Lavarino C, Chantada G, et al.
Front Pediatr
. 2025 Feb;
12:1509645.
PMID: 39895987
High-dose chemotherapy with autologous stem cell rescue has improved outcomes in patients with metastatic retinoblastoma (RB). Despite significant advances, acute and long-term side-effects, particularly in visually impaired and cancer-predisposed patients,...
2.
Planas S, Salvador N, Lavarino C, Zuccarino F, Pereda D, Munoz J, et al.
Cardiovasc Pathol
. 2024 May;
73:107660.
PMID: 38821230
Hamartoma of mature cardiac myocytes (HMCM) is an extremely rare cardiac tumor characterized by benign growth of differentiated mature striated cardiac myocytes, and usually involves the ventricular myocardium. We describe...
3.
Mora J, Climent A, Roldan M, Flores M, Varo A, Perez-Jaume S, et al.
Front Oncol
. 2024 May;
14:1380917.
PMID: 38812778
Background: Anti-GD2 monoclonal antibodies (mAbs) have shown to improve the overall survival of patients with high-risk neuroblastoma (HR-NB). Serious adverse events (AEs), including pain, within hours of antibody infusion, have...
4.
Gorostegui M, Munoz J, Perez-Jaume S, Simao-Rafael M, Larrosa C, Garraus M, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730688
Neuroblastoma presents with two patterns of disease: locoregional or systemic. The poor prognostic risk factors of locoregional neuroblastoma (LR-NB) include age, or amplification, 11q, histology, diploidy with or mutations, and...
5.
Rojas M, Munoz J, Flores-Martin J, Sanchez-Fernandez-de-Landa P, Cruz Del Puerto M, Genti-Raimondi S, et al.
FEBS J
. 2023 Oct;
291(2):338-357.
PMID: 37846201
StarD7 is a member of the START protein family required for phosphatidylcholine delivery to the mitochondria, thus key to maintain mitochondrial structure. Its deficiency has been associated with an impairment...
6.
Munoz J, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835531
Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) to induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8),...
7.
Munoz J, Basei F, Rojas M, Galvis D, Zorzano A
Biomolecules
. 2023 Aug;
13(8).
PMID: 37627290
Mitochondrial network architecture plays a critical role in cellular physiology. Indeed, alterations in the shape of mitochondria upon exposure to cellular stress can cause the dysfunction of these organelles. In...
8.
Torres-Mendez J, Nino-Narvion J, Martinez-Santos P, Diarte-Anazco E, Mendez-Lara K, Del Olmo T, et al.
Nutrients
. 2023 Jul;
15(14).
PMID: 37513501
This study investigated the effect of nicotinamide (NAM) supplementation on the development of brain inflammation and microglial activation in a mouse model of type 1 diabetes mellitus. C57BL/6J male mice,...
9.
Avellaneda N, Coy C, Fillmann H, Saad-Hossne R, Munoz J, Garcia-Duperly R, et al.
Cir Esp (Engl Ed)
. 2023 May;
101(12):824-832.
PMID: 37244420
Introduction: Complications after ileocecal resection for Crohn's disease (CD) are frequent. The aim of this study was to analyze risk factors for postoperative complications after these procedures. Materials And Methods:...
10.
Varo A, Castaneda A, Chamorro S, Munoz J, Gorostegui M, Celma M, et al.
Front Oncol
. 2023 May;
13:1164949.
PMID: 37213300
Introduction: Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm. We developed a novel method of administering...